Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE:EBS) announced FDA approval of a supplemental NDA to package OTC NARCAN® Nasal Spray in a new compact carrying case that holds two blister-packed doses with a Quick Start Guide. The case is designed for discretion and daily carry to improve readiness during opioid emergencies. Company survey data cited 74% overall and 81% among college students preferring a discreet carrying case. The release notes only 10% of consumers currently carry naloxone. The carrying case will be available soon at select retailers, online, and via NARCANDirect. Since 2016, the company reports > 85 million doses distributed in the U.S. and Canada.
Emergent BioSolutions (NYSE: EBS) said it made a voluntary prepayment of $100 million on its term loan in late December 2025 using cash on hand. The company reported that, since 2023 and with this prepayment, its gross debt has been reduced by $275 million to $593 million (pro forma as of September 30, 2025), a 32% decline in total debt since beginning its multi-year transformation plan. Management said the move improves financial flexibility and supports long-term stability and strategic initiatives. Emergent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST.
Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026. The order is placed under Emergent’s existing IDIQ contract W911SR24D0001, led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency. Deliveries will occur in 2026 and the order includes a one-year base period plus two option periods covering 2027 and 2028. The company said the award continues its partnership to provide anthrax vaccination for military personnel at elevated risk.
Emergent BioSolutions (NYSE: EBS) agreed to provide additional financial support to continue the Africa CDC-led MpOx Study in Africa (MOSA), a double-blind, platform-adaptive clinical trial launched in 2024 to evaluate treatments for mpox.
An independent data and safety monitoring board completed an initial safety review in December 2025 after 50 patients were randomized and recommended continuation with no safety concerns identified. Africa CDC and PANTHER plan to extend MOSA to additional countries, including a site in Uganda, and enroll more patients toward the next milestone.
The release notes there is currently no dedicated antiviral therapy for mpox and cites Africa CDC case totals of 61,383 confirmed cases and 296 deaths across 32 countries since 2024.
Emergent BioSolutions (NYSE: EBS) announced that Joe Papa, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 PM PST. An audio link to the session will be available and kept live for up to 30 days. The company said its presentation slides will be posted on the Investors section of the Emergent website at the time of the presentation.
Emergent BioSolutions (NYSE: EBS) announced that the U.S. FDA approved its supplemental BLA on Dec 12, 2025 to add the company's Winnipeg, Canada facility as a drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for treatment and prophylaxis of inhalational anthrax.
The Winnipeg site is described as USMCA-compliant with over 45 years of therapeutics manufacturing experience and capabilities for drug substance, fill/finish, and analytical testing. The approval follows a May 2024 operational plan to consolidate manufacturing in Winnipeg and Lansing as part of a multi-year transformation strategy.
Emergent BioSolutions (NYSE: EBS) marks the 10-year anniversary of the U.S. FDA approval of NARCAN® Nasal Spray, the first FDA‑approved nasal naloxone spray for emergency opioid overdose treatment, originally approved in November 2015 and later authorized OTC in March 2023.
The company highlights milestones: >85 million doses distributed since 2016, the 2018 acquisition of Adapt Pharma, launch of NARCANDirect, Project NEXUS real‑world evidence efforts, and product extensions including wall unit kits and convenience kits. Emergent cites a nearly 32% decline in opioid overdose deaths reported by CDC in 2024 and reaffirms commitment to naloxone access.
Emergent BioSolutions (NYSE: EBS) announced that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14, 2025 after 19 years of service.
Dr. Sullivan joined the board in 2006 and most recently served as chair of the compensation committee and as a member of the nominating and corporate governance committee. The company noted his experience in healthcare, government and biotechnology and cited his role guiding decisions during Emergent’s multi-year transformation. Dr. Sullivan previously served as president of Morehouse School of Medicine and as Secretary of the Department of Health and Human Services.
Emergent BioSolutions (NYSE: EBS) reported Q3 2025 total revenue $231.1M, beating the high end of guidance by $21.0M. Q3 net income was $51.2M (margin 22%) and adjusted EBITDA was $87.8M (margin 38%).
The company noted adjusted gross margin 61% (up 200 bps YoY), sequential naloxone revenue growth led by NARCAN nasal spray, and raised full-year 2025 revenue and profitability guidance. Emergent reported 11 MCM contract modifications/orders in 2025 and that international customers represent 34% of MCM orders YTD. Year-to-date revenue was $594.2M, down versus prior year.
Emergent BioSolutions (NYSE: EBS) released a survey of ~250 U.S. policy opinion leaders on Oct 28, 2025 showing heightened concern about biological threats and U.S. preparedness.
Key findings: 65% say the likelihood of a biological attack is rising, 45% say the U.S. is unprepared, 73% believe a biological attack would be easier to carry out than a nuclear one, and nearly 90% support continued U.S. leadership and government backing for biotech/biodefense. Emergent highlighted its >25 years of countermeasure experience and North American BSL‑2/3 manufacturing capabilities for anthrax, botulism, smallpox and viral hemorrhagic fevers.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
